JP2016106149A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016106149A5 JP2016106149A5 JP2016051146A JP2016051146A JP2016106149A5 JP 2016106149 A5 JP2016106149 A5 JP 2016106149A5 JP 2016051146 A JP2016051146 A JP 2016051146A JP 2016051146 A JP2016051146 A JP 2016051146A JP 2016106149 A5 JP2016106149 A5 JP 2016106149A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- pharmaceutically acceptable
- acceptable salt
- hepatitis
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 4
- 208000005176 Hepatitis C Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41481810P | 2010-11-17 | 2010-11-17 | |
| US61/414,818 | 2010-11-17 | ||
| US201161504924P | 2011-07-06 | 2011-07-06 | |
| US61/504,924 | 2011-07-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013539970A Division JP5905020B2 (ja) | 2010-11-17 | 2011-11-16 | 抗ウイルス化合物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017240524A Division JP2018039851A (ja) | 2010-11-17 | 2017-12-15 | 抗ウイルス化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016106149A JP2016106149A (ja) | 2016-06-16 |
| JP2016106149A5 true JP2016106149A5 (enExample) | 2016-10-20 |
Family
ID=45099196
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013539970A Active JP5905020B2 (ja) | 2010-11-17 | 2011-11-16 | 抗ウイルス化合物 |
| JP2016051146A Pending JP2016106149A (ja) | 2010-11-17 | 2016-03-15 | 抗ウイルス化合物 |
| JP2017240524A Withdrawn JP2018039851A (ja) | 2010-11-17 | 2017-12-15 | 抗ウイルス化合物 |
| JP2019206819A Withdrawn JP2020037584A (ja) | 2010-11-17 | 2019-11-15 | 抗ウイルス化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013539970A Active JP5905020B2 (ja) | 2010-11-17 | 2011-11-16 | 抗ウイルス化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017240524A Withdrawn JP2018039851A (ja) | 2010-11-17 | 2017-12-15 | 抗ウイルス化合物 |
| JP2019206819A Withdrawn JP2020037584A (ja) | 2010-11-17 | 2019-11-15 | 抗ウイルス化合物 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US9156823B2 (enExample) |
| EP (3) | EP2640719B1 (enExample) |
| JP (4) | JP5905020B2 (enExample) |
| KR (5) | KR20200140924A (enExample) |
| AR (1) | AR083711A1 (enExample) |
| AU (3) | AU2011328980B2 (enExample) |
| CA (3) | CA3095528C (enExample) |
| ES (1) | ES2634095T3 (enExample) |
| HK (1) | HK1250162A1 (enExample) |
| IL (1) | IL226346A (enExample) |
| NZ (2) | NZ726475A (enExample) |
| PL (1) | PL2640719T3 (enExample) |
| PT (1) | PT2640719T (enExample) |
| SG (2) | SG10201509456SA (enExample) |
| SI (1) | SI2640719T1 (enExample) |
| TW (3) | TWI607011B (enExample) |
| UY (1) | UY33735A (enExample) |
| WO (1) | WO2012068234A2 (enExample) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2734052A1 (en) | 2003-05-30 | 2005-01-13 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
| PE20120509A1 (es) | 2009-05-13 | 2012-05-09 | Gilead Sciences Inc | Derivados 9,9 difluoro-9h-fluoreno que tiene actividad antiviral |
| PL2455376T3 (pl) | 2009-06-11 | 2015-06-30 | Abbvie Bahamas Ltd | Związki heterocykliczne jako inhibitory wirusa zapalenia wątroby typu C (HCV) |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| EP2575475A4 (en) * | 2010-05-28 | 2013-11-27 | Presidio Pharmaceuticals Inc | HCV NS5A INHIBITORS |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| SG10201509456SA (en) | 2010-11-17 | 2015-12-30 | Gilead Pharmasset Llc | Antiviral compounds |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| UA116087C2 (uk) | 2011-09-16 | 2018-02-12 | Гіліад Фармассет Елелсі | Композиція для лікування вірусу гепатиту c |
| AP2013006877A0 (en) * | 2011-11-16 | 2013-05-31 | Gilead Sciences Inc | Antiviral compounds |
| AU2015252077A1 (en) * | 2011-11-16 | 2015-11-19 | Gilead Pharmasset Llc | Antiviral compounds |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9073943B2 (en) | 2012-02-10 | 2015-07-07 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
| US20130309196A1 (en) * | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
| US9079887B2 (en) * | 2012-05-16 | 2015-07-14 | Gilead Sciences, Inc. | Antiviral compounds |
| US9233974B2 (en) * | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
| MY172166A (en) | 2013-01-31 | 2019-11-15 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| WO2014122895A1 (ja) * | 2013-02-07 | 2014-08-14 | 保土谷化学工業株式会社 | ジアザトリフェニレン環構造を有する化合物および有機エレクトロルミネッセンス素子 |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| WO2014185995A1 (en) * | 2013-05-16 | 2014-11-20 | Gilead Pharmasset Llc | Hepatitis c treatments with sofosbuvir |
| CN104211677B (zh) * | 2013-05-30 | 2018-02-23 | 浙江九洲药业股份有限公司 | 一种抗丙型肝炎药物中间体的制备方法 |
| CN104211565A (zh) * | 2013-05-31 | 2014-12-17 | 浙江九洲药业股份有限公司 | 一种抗丙型肝炎药物中间体的制备方法 |
| CA2915517A1 (en) | 2013-06-26 | 2014-12-31 | Zhejiang Jiuzhou Pharmaceutical Co., Ltd. | Preparation method for pyrrolidine-2-carboxylic acid derivatives |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| EP3021845A1 (en) | 2013-07-17 | 2016-05-25 | Bristol-Myers Squibb Company | Combinations comprising biphenyl derivatives for use in the treatment of hcv |
| WO2015030854A1 (en) * | 2013-08-27 | 2015-03-05 | Gilead Pharmasset Llc | Solid dispersion formulation of an antiviral compound |
| SG11201600919UA (en) * | 2013-08-27 | 2016-03-30 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| CN104418784B (zh) * | 2013-09-04 | 2019-02-19 | 浙江九洲药业股份有限公司 | 一种抗病毒药物中间体的拆分方法 |
| WO2015089810A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Fused tetracyclic heterocyclic compounds and methods of use thereof for the treatment of viral diseases |
| AU2014375584B2 (en) * | 2013-12-31 | 2017-11-09 | Nanjing Sanhome Pharmaceutical Co., Ltd. | 9,9,10,10-tetrafluoro-9,10-dihydrophenanthrene hepatitis C virus inhibitor and application thereof |
| EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
| WO2015184644A1 (zh) * | 2014-06-06 | 2015-12-10 | 爱博新药研发(上海)有限公司 | 抑制丙肝病毒的化合物、药物组合物及其应用 |
| TWI721947B (zh) * | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
| TWI679203B (zh) * | 2014-06-11 | 2019-12-11 | 美商基利法瑪席特有限責任公司 | 製備抗病毒化合物之方法 |
| US20150361087A1 (en) * | 2014-06-12 | 2015-12-17 | Gilead Sciences, Inc. | Antiviral compounds |
| EP3939985B1 (en) | 2014-12-26 | 2024-05-08 | Emory University | Pharmaceutical compositions comprising n4-hydroxycytidine derivatives for the treatment or prevention of influenza or coronavirus infections |
| CN104592124B (zh) * | 2015-01-04 | 2018-01-02 | 华南理工大学 | 一种萘[1,2]并咪唑双极性共轭化合物及制备与应用 |
| CN105968101B (zh) * | 2015-03-12 | 2019-03-01 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的化合物及其在药物中的应用 |
| CN106256819B (zh) * | 2015-06-19 | 2019-07-09 | 重庆博腾制药科技股份有限公司 | 一种(4S)-N-Boc-4-甲氧基甲基-L-脯氨酸胺盐的合成方法 |
| WO2016202232A1 (zh) * | 2015-06-19 | 2016-12-22 | 重庆博腾制药科技股份有限公司 | 一种(4S)-N-Boc-4-甲氧基甲基-L-脯氨酸胺盐的合成方法 |
| US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| KR101919194B1 (ko) * | 2015-09-15 | 2018-11-15 | 주식회사 엘지화학 | 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자 |
| WO2017181383A1 (en) * | 2016-04-21 | 2017-10-26 | Merck Sharp & Dohme Corp. | Hepatitis c virus inhibitors |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| ES2990061T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros espirocíclicos para la degradación de proteínas diana |
| CN109414508A (zh) | 2016-05-27 | 2019-03-01 | 吉利德科学公司 | 使用ns5a、ns5b或ns3抑制剂治疗乙型肝炎病毒感染的方法 |
| CN106432197B (zh) * | 2016-09-07 | 2019-12-10 | 上海众强药业有限公司 | 一种雷迪帕韦中间体单对甲苯磺酸盐、其晶型及其制备方法 |
| CN110698489B (zh) * | 2016-11-30 | 2022-02-22 | 上海新礼泰药业有限公司 | 维帕他韦中间体、制备方法及应用 |
| WO2018138050A1 (de) | 2017-01-26 | 2018-08-02 | Bayer Aktiengesellschaft | Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| ES2995458T3 (en) | 2017-12-07 | 2025-02-10 | Univ Emory | N4-hydroxycytidine derivative and anti-viral uses related thereto |
| KR102708681B1 (ko) | 2018-02-13 | 2024-09-26 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| EP3781556B1 (en) | 2018-04-19 | 2025-06-18 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| WO2019222146A1 (en) | 2018-05-15 | 2019-11-21 | University Of Louisville Research Foundation, Inc. | Urolithin a and derivatives thereof for use in therapy |
| PL3820572T3 (pl) | 2018-07-13 | 2024-02-26 | Gilead Sciences, Inc. | Inhibitory pd-1/pd-l1 |
| CA3117199C (en) | 2018-10-24 | 2024-03-19 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| KR102316919B1 (ko) | 2019-11-28 | 2021-10-22 | 서울시립대학교 산학협력단 | 피지컬 컴퓨팅 소프트웨어를 이용한 코딩 교육 교재 및 이를 활용한 코딩 교육 방법 |
| CN111018870B (zh) * | 2019-11-29 | 2021-07-23 | 南京正济医药研究有限公司 | 一种维帕他韦中间体的制备方法 |
| WO2021138540A1 (en) | 2020-01-03 | 2021-07-08 | Berg Llc | Polycyclic amides as ube2k modulators for treating cancer |
| WO2021209563A1 (en) | 2020-04-16 | 2021-10-21 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
| CN112877379B (zh) * | 2021-01-18 | 2023-09-01 | 华南理工大学 | 一种化学酶法合成n-[(3r,6r)-6-甲基哌啶-3-基]氨基甲酸叔丁酯的方法 |
| US12497408B2 (en) * | 2021-05-21 | 2025-12-16 | Gilead Sciences, Inc. | Tetracyclic compounds and methods for the treatment of Zika virus infection |
| US12037340B2 (en) | 2021-05-21 | 2024-07-16 | Gilead Sciences, Inc. | Pentacyclic derivatives as Zika virus inhibitors |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| JP3347723B2 (ja) | 1990-06-13 | 2002-11-20 | グラツィエル，アーノルド | 含リンプロドラッグ |
| DK0481214T3 (da) | 1990-09-14 | 1999-02-22 | Acad Of Science Czech Republic | Prolægemidler af phosphonater |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| US5858389A (en) | 1996-08-28 | 1999-01-12 | Shaker H. Elsherbini | Squalene is an antiviral compound for treating hepatitis C virus carriers |
| CA2448737C (en) | 2001-07-20 | 2010-06-01 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| ES2456702T3 (es) | 2003-05-09 | 2014-04-23 | Boehringer Ingelheim International Gmbh | Bolsillo de unión del inhibidor de la polimerasa NS5B del virus de la hepatitis C |
| US7157492B2 (en) | 2004-02-26 | 2007-01-02 | Wyeth | Dibenzo chromene derivatives and their use as ERβ selective ligands |
| EP1778702B1 (en) | 2004-07-16 | 2011-07-13 | Gilead Sciences, Inc. | Antiviral compounds |
| CN101160324B (zh) * | 2005-02-18 | 2013-04-24 | 米德列斯公司 | 缺乏岩藻糖残基的抗前列腺特异性膜抗原(psma)单克隆抗体 |
| US8891379B2 (en) | 2006-06-02 | 2014-11-18 | Riverbed Technology, Inc. | Traffic flow inference based on link loads and gravity measures |
| US7759495B2 (en) * | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7659270B2 (en) * | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2823981C (en) | 2006-12-07 | 2016-05-17 | Daiichi Sankyo Company, Limited | Film-coated preparation having improved stability |
| US7741347B2 (en) | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| MX2010008650A (es) * | 2008-02-12 | 2010-08-30 | Bristol Myers Squibb Co | Inhibidores de virus de la hepatitis c. |
| US8147818B2 (en) * | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7704992B2 (en) | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2715839C (en) * | 2008-02-13 | 2014-12-09 | Bristol-Myers Squibb Company | Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors |
| US20100256184A1 (en) | 2008-08-13 | 2010-10-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US8729077B2 (en) * | 2008-11-28 | 2014-05-20 | Glaxosmithkline Llc | Anti-viral compounds, compositions, and methods of use |
| AU2009322387A1 (en) * | 2008-12-03 | 2011-06-30 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
| CA2753313A1 (en) * | 2009-02-23 | 2010-08-26 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| KR20130130875A (ko) * | 2009-02-27 | 2013-12-02 | 이난타 파마슈티칼스, 인코포레이티드 | Ｃ형 간염 바이러스 억제제 |
| CA2756255A1 (en) | 2009-03-27 | 2010-09-30 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic hcv inhibitors |
| US9150554B2 (en) | 2009-03-27 | 2015-10-06 | Presidio Pharmaceuticals, Inc. | Fused ring inhibitors of hepatitis C |
| JP2012526834A (ja) | 2009-05-12 | 2012-11-01 | シェーリング コーポレイション | ウイルス疾患治療に有用な縮合型三環式アリール化合物 |
| PE20120509A1 (es) * | 2009-05-13 | 2012-05-09 | Gilead Sciences Inc | Derivados 9,9 difluoro-9h-fluoreno que tiene actividad antiviral |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| US8138215B2 (en) * | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN102480971B (zh) | 2009-09-04 | 2014-11-26 | 杨森制药公司 | 化合物 |
| US9156818B2 (en) * | 2009-09-11 | 2015-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US20120276047A1 (en) | 2009-11-25 | 2012-11-01 | Rosenblum Stuart B | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
| US8377980B2 (en) * | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN104530079B (zh) | 2009-12-18 | 2017-10-20 | 北京凯因科技股份有限公司 | C型肝炎病毒复制的新型抑制剂 |
| WO2011087740A1 (en) * | 2009-12-22 | 2011-07-21 | Schering Corporation | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases |
| EP2545060B1 (en) | 2010-03-09 | 2015-11-25 | Merck Sharp & Dohme Corp. | Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases |
| US9125904B1 (en) * | 2010-05-11 | 2015-09-08 | Achillion Pharmaceuticals, Inc. | Biphenyl imidazoles and related compounds useful for treating HCV infections |
| US20110312996A1 (en) * | 2010-05-17 | 2011-12-22 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| EP2616461A4 (en) * | 2010-08-26 | 2014-03-26 | Rfs Pharma Llc | POTENTIVE AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS |
| WO2012048421A1 (en) * | 2010-10-14 | 2012-04-19 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
| SG10201509456SA (en) | 2010-11-17 | 2015-12-30 | Gilead Pharmasset Llc | Antiviral compounds |
| WO2012087976A2 (en) | 2010-12-21 | 2012-06-28 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| AP2013006877A0 (en) | 2011-11-16 | 2013-05-31 | Gilead Sciences Inc | Antiviral compounds |
| US9079887B2 (en) | 2012-05-16 | 2015-07-14 | Gilead Sciences, Inc. | Antiviral compounds |
| US20130309196A1 (en) | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
| US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
| SG11201600919UA (en) | 2013-08-27 | 2016-03-30 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| WO2015030854A1 (en) | 2013-08-27 | 2015-03-05 | Gilead Pharmasset Llc | Solid dispersion formulation of an antiviral compound |
| TWI679203B (zh) | 2014-06-11 | 2019-12-11 | 美商基利法瑪席特有限責任公司 | 製備抗病毒化合物之方法 |
| TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
| JP2016051146A (ja) | 2014-09-02 | 2016-04-11 | ウシオ電機株式会社 | 光検出装置 |
-
2011
- 2011-11-16 SG SG10201509456SA patent/SG10201509456SA/en unknown
- 2011-11-16 UY UY33735A patent/UY33735A/es not_active Application Discontinuation
- 2011-11-16 TW TW105118984A patent/TWI607011B/zh active
- 2011-11-16 EP EP11791700.5A patent/EP2640719B1/en active Active
- 2011-11-16 US US13/884,578 patent/US9156823B2/en active Active
- 2011-11-16 NZ NZ726475A patent/NZ726475A/en unknown
- 2011-11-16 CA CA3095528A patent/CA3095528C/en active Active
- 2011-11-16 WO PCT/US2011/060966 patent/WO2012068234A2/en not_active Ceased
- 2011-11-16 EP EP19215845.9A patent/EP3699176A3/en not_active Withdrawn
- 2011-11-16 CA CA2817840A patent/CA2817840A1/en not_active Abandoned
- 2011-11-16 KR KR1020207034568A patent/KR20200140924A/ko not_active Ceased
- 2011-11-16 JP JP2013539970A patent/JP5905020B2/ja active Active
- 2011-11-16 SG SG2013036223A patent/SG190785A1/en unknown
- 2011-11-16 PL PL11791700T patent/PL2640719T3/pl unknown
- 2011-11-16 NZ NZ710567A patent/NZ710567A/en unknown
- 2011-11-16 KR KR1020187005807A patent/KR20180026563A/ko not_active Ceased
- 2011-11-16 TW TW100141839A patent/TWI548629B/zh active
- 2011-11-16 PT PT117917005T patent/PT2640719T/pt unknown
- 2011-11-16 KR KR1020137015201A patent/KR101835474B1/ko active Active
- 2011-11-16 KR KR1020197036217A patent/KR20190140486A/ko not_active Ceased
- 2011-11-16 TW TW106129863A patent/TWI640526B/zh active
- 2011-11-16 KR KR1020197002491A patent/KR20190012271A/ko not_active Ceased
- 2011-11-16 CA CA3102625A patent/CA3102625C/en active Active
- 2011-11-16 AR ARP110104276 patent/AR083711A1/es active IP Right Grant
- 2011-11-16 SI SI201131200A patent/SI2640719T1/sl unknown
- 2011-11-16 AU AU2011328980A patent/AU2011328980B2/en active Active
- 2011-11-16 EP EP17169675.0A patent/EP3284741A1/en not_active Withdrawn
- 2011-11-16 ES ES11791700.5T patent/ES2634095T3/es active Active
-
2013
- 2013-05-13 IL IL226346A patent/IL226346A/en active IP Right Grant
-
2015
- 2015-07-30 US US14/814,392 patent/US10344019B2/en active Active
-
2016
- 2016-03-15 JP JP2016051146A patent/JP2016106149A/ja active Pending
-
2017
- 2017-04-13 AU AU2017202461A patent/AU2017202461A1/en not_active Abandoned
- 2017-12-15 JP JP2017240524A patent/JP2018039851A/ja not_active Withdrawn
-
2018
- 2018-07-24 HK HK18109580.7A patent/HK1250162A1/en unknown
-
2019
- 2019-03-20 AU AU2019201939A patent/AU2019201939C1/en active Active
- 2019-05-23 US US16/421,330 patent/US20200123132A1/en not_active Abandoned
- 2019-11-15 JP JP2019206819A patent/JP2020037584A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016106149A5 (enExample) | ||
| JP2017186358A5 (enExample) | ||
| JP2014507446A5 (enExample) | ||
| JP2018024670A5 (enExample) | ||
| JP2017105793A5 (enExample) | ||
| HRP20230274T1 (hr) | Kemijski spojevi | |
| JP2016034978A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2020097577A5 (enExample) | ||
| JP2021502388A5 (enExample) | ||
| JP2014156468A5 (enExample) | ||
| JP2018048154A5 (enExample) | ||
| JP2012532874A5 (enExample) | ||
| JP2017533930A5 (enExample) | ||
| JP2016522254A5 (enExample) | ||
| JP2016539157A5 (enExample) | ||
| EA201890654A1 (ru) | Терапевтические композиции для лечения вируса иммунодефицита человека | |
| JP2016510326A5 (enExample) | ||
| JP2016540015A5 (enExample) | ||
| JP2015516419A5 (enExample) | ||
| JP2018501215A5 (enExample) | ||
| JP2019529514A5 (enExample) | ||
| HRP20191121T1 (hr) | Tretman multiple skleroze | |
| JP2016532632A5 (enExample) | ||
| JP2017516835A5 (enExample) |